STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #501 by analyst upside · 2026-06-27
KURA
Kura Oncology, Inc.
Healthcare · Market Cap $968M · P/E 0x
ANALYST PRICE TARGET
+185.9%
implied upside to consensus target
Current Price $10.9
Consensus Target $31.17
Bull Target $76.0
Bear Target $15.0
Analysts Covering 12
ANALYST CONSENSUS — BUY
Strong Buy
2
Buy
9
Hold
1
Sell
0
52-Week Low $5.45
52-Week High $12.49
YTD Return +5.5%
FUNDAMENTALS
Market Cap $968M
P/E Ratio (TTM) N/A
Forward P/E -4.2x
EPS (TTM) $-3.52
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $72M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $5.45
52-Week High $12.49
Current Price $10.9
Bear Target $15.0
Bull Target $76.0
● Now $10.9 ● Target $31.17
TRADING DATA
Avg Volume 1.7M
YTD Return +5.5%
Analyst Count 12
Consensus Buy
Upside to Target +185.9%
Last Updated 2026-06-27

ANALYST SUMMARY

Kura Oncology, Inc. (KURA) is currently trading at $10.9 with a Wall Street consensus price target of $31.17, implying potential upside of 185.9% over the next 12 months. 12 analysts currently cover KURA, with a consensus rating of Buy — 92% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $76.0, while the most cautious has a target of $15.0.

KURA operates in the Healthcare sector with a market capitalisation of $968M. The stock is up 5.5% year-to-date and is currently trading near the upper end of its 52-week range of $5.45 – $12.49.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for KURA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Citizens reit
Market Outperform → Market Outperform 2026-06-15 Building track record
Lake Street ● Initiated
Buy 2026-04-14 27% win rate (11 calls)
Mizuho — Reiterated
Outperform → Outperform 2026-03-24 Building track record
UBS — Reiterated
Buy → Buy 2026-03-13 33% win rate (6 calls)
Wedbush — Reiterated
Outperform → Outperform 2026-03-06 Building track record
Leerink Partners — Reiterated
Outperform → Outperform 2026-01-13 29% win rate (7 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-01-13 31% win rate (48 calls)
Barclays — Reiterated
Overweight → Overweight 2025-11-24 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →